Monsoon Twilight Investor Briefing Presentation
Arovella CEO and MD, Dr Michael Baker, will present key pre-clinical data for Arovella’s iNKT cell therapy platform and described how Arovella’s technology provides important advantages over existing T-cell therapies and has the potential to be applied to both blood cancers and solid tumours.